To directly examine how the host TNF signaling affects Ruxo efficacy, we inoculated TNF−/− mice lacking TNF in host cells, including immune cells (T cells, myeloid cells, etc.), with IFNγR1KO melanoma cells, followed by Ruxo treatment. Here, TNF is linked to melanoma.